Previous studies have revealed that inhibiting NLRP3 inflammasome activation in macrophages and thereby attenuating myocardial IL‐1β and IL‐18 levels effectively ameliorates myocardial ischemic injury and pressure overload‐induced heart failure and cardiac remodeling.11, 12, 13. Here, IL1B is linked to heart failure.